Oregon Medical Board
Chapter 847
Division 15
GENERAL LICENSING RULES, RELATING TO CONTROLLED SUBSTANCES
847-015-0010
Schedule III or IV Controlled Substances — Bariatrics Practice
(1) A licensee shall not utilize a Schedule III or IV controlled substance for purposes of weight reduction, other than in accordance with federal Food and Drug Administration (FDA) product guidelines in effect at the time of utilization and with all the provisions of this rule.
(2) A licensee may utilize a Schedule III or IV controlled substance for purposes of weight reduction in the treatment of Exogenous Obesity in a regimen of weight reduction based on caloric restriction, behavior modification and prescribed exercise, provided that all of the following conditions are met:
(a) Before initiating treatment utilizing a Schedule III or IV controlled substance, the licensee thoroughly reviews the licensee’s own records of prior treatment, or thoroughly reviews the records of prior treatment which another treating health care professional or weight-loss program has provided to the licensee, that one of the following conditions exist:
(A) Patient's body mass index exceeds 30 Kg/M sq; or
(B) Patient's body mass index exceeds 27 Kg/M sq and the excess weight represents a threat to the patient's health (as with hypertension, diabetes, or hypercholesterolemia.)
(b) Before initiating treatment utilizing a Schedule III or IV controlled substance, the licensee obtains a thorough history, performs a thorough physical examination of the patient, and rules out the existence of any recognized contraindications to the use of the controlled substance to be utilized.
(3) Continuation of Schedule III or IV designated as FDA short term use controlled substances beyond three (3) months requires documentation of an average two (2) pound per month weight loss during active weight reduction treatment, or documentation of maintenance of goal weight. Use of Schedule III or IV controlled substances with FDA approval for bariatric therapy and designated for long term use where FDA guidelines are followed may also be used beyond three months.
(4) A violation of any provision of this rule, as determined by the Board, shall constitute Unprofessional Conduct as the term is used in ORS 677.188(4)(a), (b), or (c), whether or not actual injury to a patient is established.
Statutory/Other Authority: ORS 677.265
Statutes/Other Implemented: ORS 677.188(4) & 677.190(24)
History:
OMB 8-2016, f. & cert. ef. 7-8-16
BME 4-2001, f. & cert. ef. 1-25-01
BME 17-2000(Temp), f. & cert. ef. 10-30-00 thru 2-28-01
BME 9-1998, f. & cert. ef. 7-22-98
ME 1-1997, f. & cert. ef. 1-28-97
ME 1-1995, f. & cert. ef. 2-1-95
ME 1-1987, f. & ef. 1-20-87